Drug Profile
BTI 322
Alternative Names: Anti-CD2 monoclonal antibody; Lo-CD2-a; Monoclonal antibody Lo-CD2-aLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Catholic University of Louvain
- Developer AstraZeneca; BioTransplant; BioTransplant (CEASED); MedImmune
- Class Monoclonal antibodies
- Mechanism of Action CD2 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autoimmune disorders; Graft-versus-host disease; Liver transplant rejection; Renal transplant rejection
Most Recent Events
- 19 Jun 2007 MedImmune has been acquired by AstraZeneca
- 12 Mar 2004 It appears that BioTransplant has ceased operations
- 12 Mar 2004 Discontinued - Phase-II for Graft-versus-host disease in USA (IV)